3-Oxo-5-alpha-Steroid 4-Dehydrogenase

"3-Oxo-5-alpha-Steroid 4-Dehydrogenase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An enzyme that catalyzes the reduction of TESTOSTERONE to 5-ALPHA DIHYDROTESTOSTERONE.

Descriptor ID

D013741

MeSH Number(s)

D08.811.682.660.465

Concept/Terms

3-Oxo-5-alpha-Steroid 4-Dehydrogenase

Below are MeSH descriptors whose meaning is more general than "3-Oxo-5-alpha-Steroid 4-Dehydrogenase".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Oxidoreductases [D08.811.682]
Oxidoreductases Acting on CH-CH Group Donors [D08.811.682.660]
3-Oxo-5-alpha-Steroid 4-Dehydrogenase [D08.811.682.660.465]

Below are MeSH descriptors whose meaning is related to "3-Oxo-5-alpha-Steroid 4-Dehydrogenase".

Below are MeSH descriptors whose meaning is more specific than "3-Oxo-5-alpha-Steroid 4-Dehydrogenase".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "3-Oxo-5-alpha-Steroid 4-Dehydrogenase" by people in Harvard Catalyst Profiles by year, and whether "3-Oxo-5-alpha-Steroid 4-Dehydrogenase" was a major or minor topic of these publication.

Bar chart showing 29 publications over 18 distinct years, with a maximum of 4 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	2	0	2
1998	0	1	1
1999	1	0	1
2000	1	0	1
2002	0	1	1
2003	0	3	3
2004	0	2	2
2006	1	0	1
2007	1	1	2
2008	0	1	1
2009	0	1	1
2011	0	1	1
2012	0	2	2
2013	1	0	1
2015	2	0	2
2016	0	1	1
2017	2	2	4
2020	1	1	2

Below are the most recent publications written about "3-Oxo-5-alpha-Steroid 4-Dehydrogenase" by people in Profiles.

Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy. PLoS One. 2020; 15(3):e0229754.

View in: PubMed
Obesity-associated inflammation induces androgenic to estrogenic switch in the prostate gland. Prostate Cancer Prostatic Dis. 2020 09; 23(3):465-474.

View in: PubMed
Androgenic to oestrogenic switch in the human adult prostate gland is regulated by epigenetic silencing of steroid 5a-reductase 2. J Pathol. 2017 12; 243(4):457-467.

View in: PubMed
Direct Metabolic Interrogation of Dihydrotestosterone Biosynthesis from Adrenal Precursors in Primary Prostatectomy Tissues. Clin Cancer Res. 2017 Oct 15; 23(20):6351-6362.

View in: PubMed
Effects of testosterone administration (and its 5-alpha-reduction) on parenchymal organ volumes in healthy young men: findings from a dose-response trial. Andrology. 2017 Sep; 5(5):889-897.

View in: PubMed
Effects of a co-micronized composite containing palmitoylethanolamide and polydatin in an experimental model of benign prostatic hyperplasia. Toxicol Appl Pharmacol. 2017 08 15; 329:231-240.

View in: PubMed
Meta-analysis identifies novel risk loci and yields systematic insights into the biology of male-pattern baldness. Nat Commun. 2017 03 08; 8:14694.

View in: PubMed
Chrysophanic acid reduces testosterone-induced benign prostatic hyperplasia in rats by suppressing 5a-reductase and extracellular signal-regulated kinase. Oncotarget. 2017 Feb 07; 8(6):9500-9512.

View in: PubMed
Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature. 2016 05 26; 533(7604):547-51.

View in: PubMed
Age and Obesity Promote Methylation and Suppression of 5a-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia. J Urol. 2015 Oct; 194(4):1031-7.

View in: PubMed

Related Networks

People

Explore

Similar Concepts

Top Journals

Cancer Res
J Neurochem
Brain Res
J Urol
Cancer Epidemiol Biomarkers Prev
Urology
Clin Cancer Res
Andrology
Am J Pathol
Am J Med Genet B Neuropsychiatr Genet